Cost-effectiveness analysis of rezivertinib and gefitinib in patients with EGFR-mutated advanced non-small cell lung cancer

Rezivertinib demonstrates significantly better cost-effectiveness compared to gefitinib for first-line treatment of EGFR-mutated advanced NSCLC in China.

Authors

Institutions

Publication Details

Journal
Expert Review of Pharmacoeconomics & Outcomes Research
Published
2026-02-03
DOI
https://doi.org/10.1080/14737167.2026.2626573
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cost-effectiveness analysis of rezivertinib and gefitinib in patients with EGFR-mutated advanced non-small cell lung cancer

Conghui Kou, lihui liu, Jing Nie, Huina Wu et al.
Expert Review of Pharmacoeconomics & Outcomes Research
Lung Cancer Treatments and Mutations
article

Cost-effectiveness analysis of rezivertinib and gefitinib in patients with EGFR-mutated advanced non-small cell lung cancer

Conghui Kou, lihui liu, Jing Nie, Huina Wu, Xifeng Zhao
article en

Abstract

Rezivertinib demonstrates significantly better cost-effectiveness compared to gefitinib for first-line treatment of EGFR-mutated advanced NSCLC in China.

Expert Review of Pharmacoeconomics & Outcomes ResearchVol. 26(3)
Shandong First Medical University (CN)
Good health and well-being
Openalex Percentile: Top 69%
Lung Cancer Treatments and Mutations
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Cost-effectiveness analysis of rezivertinib and gefitinib in patients with EGFR-mutated advanced non-small cell lung cancer — Conghui Kou, lihui liu, et al. · Expert Review of Pharmacoeconomics & Outcomes Research (2026) | TGRS Research Map | TGRS